In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated ...

Although Lilly started consistently raising its dividend in 2015, investors should be aware of some details around the schedule of these payments. Every year since then, Lilly announced a hike to its ...

High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in ...

FTC sues top PBMs for inflating insulin prices, accusing them of rigging competition and hurting patients. Legal action also includes GPOs.

Health-care company stocks fell as U.S. regulators look to crack down on prices and companies battle over market share of popular drugs. The Federal Trade Commission sued the drug middlemen that ...

Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...

The Federal Trade Commission on Friday sued prescription-drug middlemen owned by CVS Health Corp., Cigna Group and UnitedHealth Group Inc., alleging that they artificially pumped up prices of insulin ...

The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive ...

The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of steering diabetes patients toward higher-priced insulin in order to reap ...